Axitinib after Treatment Failure with Sunitinib or Cytokines in Advanced Renal Cell Carcinoma-Systematic Literature Review of Clinical and Real-World Evidence.

Autor: Sharma A; Mount Vernon Cancer Centre, Northwood HA6 2RN, UK., Bahl A; University Hospitals Bristol & Weston NHS Trust, Bristol BS2 8ED, UK., Frazer R; Velindre Cancer Centre, Cardiff CF14 2TL, UK., Godhania E; Pfizer Ltd., Walton Oaks, Tadworth KT20 7NS, UK., Halfpenny N; Open Health Group, 3068 AV Rotterdam, The Netherlands., Hartl K; Open Health Group, 10117 Berlin, Germany., Heldt D; Open Health Group, 10117 Berlin, Germany., McGrane J; Royal Cornwall Hospitals NHS Trust (Treliske), Truro TR1 3LJ, UK., Şahbaz Gülser S; Open Health Group, 3068 AV Rotterdam, The Netherlands., Venugopal B; Beatson West of Scotland Cancer Centre, Glasgow G12 0YN, UK., Ritchie A; Pfizer Ltd., Walton Oaks, Tadworth KT20 7NS, UK., Crichton K; Pfizer Ltd., Walton Oaks, Tadworth KT20 7NS, UK.
Jazyk: angličtina
Zdroj: Cancers [Cancers (Basel)] 2024 Jul 30; Vol. 16 (15). Date of Electronic Publication: 2024 Jul 30.
DOI: 10.3390/cancers16152706
Abstrakt: Background: We conducted a systematic literature review (SLR) to identify clinical evidence on treatments in advanced renal cell carcinoma (aRCC) after the failure of prior therapy with cytokines, tyrosine kinase inhibitors, or immune checkpoint inhibitors. Herein, we summarise the evidence for axitinib in aRCC after the failure of prior therapy with cytokines or sunitinib.
Methods: This SLR was registered with PROSPERO (CRD42023492931) and followed the 2020 PRISMA statement and the Cochrane guidelines. Comprehensive searches were conducted in MEDLINE and Embase as well as for conference proceedings. Study eligibility was defined according to population, intervention, comparator, outcome, and study design.
Results: Of 1252 titles/abstracts screened, 266 peer-reviewed publications were reviewed, of which 182 were included. In addition, 28 conference abstracts were eligible. Data on axitinib were reported in 55 publications, of which 16 provided efficacy and/or safety outcomes on axitinib after therapy with sunitinib or cytokines. In these patients, median progression-free and overall survival ranged between 5.5 and 8.7 months and 11.0 and 69.5 months, respectively.
Conclusions: Axitinib is commonly used in clinical practice and has a well-characterised safety and efficacy profile in the treatment of patients with aRCC after the failure of prior therapy with sunitinib or cytokines.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje